Pharmaceutical

Madrigal Pharmaceuticals (NASDAQ:MDGL) announced positive results from a double-blind, placebo-controlled, multi-center, 12-week Phase 2 clinical trial in patients with heterozygous familial hypercholesterolemia (HeFH), a severe genetic dyslipidemia that causes early onset cardiovascular disease. MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist medication. MGL-3196 is also being developed as a treatment …

Madrigal Pharmaceuticals (NASDAQ:MDGL) announced positive results from a double-blind, placebo-controlled, multi-center, 12-week Phase 2 clinical trial in patients with heterozygous familial hypercholesterolemia (HeFH), a severe genetic dyslipidemia that causes early onset cardiovascular disease. MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist medication. MGL-3196 is also being developed as a treatment for patients with non-alcoholic steatohepatitis (NASH).

As quoted in the press release:

MGL-3196 was well-tolerated with primarily mild and some moderate AEs, the numbers of which were balanced between placebo and drug-treatment groups. Fewer than 7% of patients did not complete the study, and patients who discontinued for AEs, all mild to moderate, were balanced between drug-treated and placebo patients. There were 2 serious adverse events in the study, both unrelated to treatment, one in a placebo and one in a drug-treated patient.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20206.41+106.60
TSXV700.54+3.89
DOW32223.42+26.76
S&P 5004008.01-15.88
NASD11662.79-142.21
ASX7093.00+17.90

COMMODITIES

Commodities
Gold1822.43-4.83
Silver21.56-0.04
Copper4.23+0.03
Palladium2003.00-7.00
Platinum945.50+0.50
Oil113.65-0.55
Heating Oil3.76-0.01
Natural Gas8.08+0.12

DOWNLOAD FREE REPORTS

×